Results 51 to 60 of about 2,233 (157)

Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies

European Journal of Clinical Investigation, Volume 56, Issue 10, October 2026.
COPD is a heterogeneous disease driven by overlapping neutrophilic and eosinophilic inflammatory pathways. This review highlights the shift from symptom‐based treatment toward phenotype‐ and biomarker‐directed care. Blood eosinophils, FeNO, and IgE predict corticosteroid responsiveness and identify candidates for biologic therapy.
Sasha Raman, Sreya Rahman, Francesca Polverino, Muhammad Adrish   +3 more
wiley   +1 more source

Tezepelumab\u27s Effects on Patient-Reported Symptoms in Severe Asthma, Overall and With History of Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Background Tezepelumab (an anti-thymic stromal lymphopoietin monoclonal antibody) treatment resulted in reduced exacerbations and improved sino-nasal symptoms and health-related quality of life in patients with severe uncontrolled asthma (SUA) and ...
Ambrose, Christopher S., Lugogo, Njira L., Chandarana, Shradha, Martin, Nicole, Lee, Stella E., Margolis, Mary Kay, Han, Joseph K., Kraft, Monica, Shenoy, Sonia F., Peters, Anju T.   +9 more
core   +1 more source

Italian translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Real-life effectiveness of tezepelumab in severe asthma

Allergologia et Immunopathologia
Background: Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes. Methods: This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.
Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández, null RE-ASGRAMUR GROUP   +16 more
openaire   +2 more sources

Tezepelumab in Real-Life Practice:Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe Asthma

BACKGROUND: Tezepelumab holds significant potential in severe asthma owing to its upstream target in the inflammatory cascade and could be an appropriate choice of biologic for different patient groups.OBJECTIVES: We aimed to characterize the patients ...
Hansen, Susanne, Johansson, Sofie Lock, Ulrik, Charlotte Suppli, Porsbjerg, Celeste, Bonnesen, Barbara, von Bülow, Anna, Soendergaard, Marianne Baastrup, Schmid, Johannes Martin, Haakansson, Kjell Erik Julius, Johnsen, Claus Rikard, Rasmussen, Linda Makowska, Krogh, Niels Steen, Bjerrum, Anne-Sofie, Vijdea, Roxana, Hilberg, Ole, Bjerrum, Anne Sofie   +15 more
core   +1 more source

Three-dimensional bronchial tree visualization in exercise-induced severe asthma following tezepelumab treatment

Airway hyperresponsiveness, a key feature of asthma, is associated with exercise-induced asthma. Tezepelumab was reported to reduce airway hyperresponsiveness.
Yuichi Hishida, RT, Yoshiro Kai, MD, PhD
core   +1 more source

Tezepelumab-ekko

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Basophils and tezepelumab

Statistical model results for clinical, functional, and treatment outcomes after 12 months of tezepelumab ...
diana betancor
core  

Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis

BACKGROUND: Thymic stromal lymphopoietin (TSLP) and its functional cleavage products are elevated in nasal polyps (NPs) and play important roles in type 2 (T2) inflammation in chronic rhinosinusitis (CRS) with NPs (CRSwNP) by activating myeloid dendritic
Stevens, Whitney W., Fujieda, Shigeharu, Welch, Kevin C., Kern, Robert C., Oka, Aiko, Smith, Stephanie S., Okano, Mitsuhiro, Tan, Bruce K., Bai, Junqin, Poposki, Julie A., Kidoguchi, Masanori, Schleimer, Robert P., Conley, David B., Grammer, Leslie C., Kato, Atsushi, Suh, Lydia A., Peters, Anju T., Klingler, Aiko I.   +17 more
core   +1 more source

Tezepelumab treatment in severe asthma with recurrent chronic rhinosinusitis with nasal polyps: Case series

Background: Tezepelumab is a human IgG2 mAb that inhibits thymic stromal lymphopoietin (TSLP) and is approved for treatment of severe asthma. Bronchial asthma, usually a type 2 inflammatory disease, often co-occurs with chronic rhinosinusitis with nasal ...
Yoshiro Kai, MD, PhD
core   +1 more source